NEW YORK — Abbott on Wednesday announced that its Q1 2025 Diagnostics revenues declined 7 percent year over year, while its total revenues grew 4 percent. For the three months ended March 31, Abbott ...

The agency could continue to pursue more extensive LDT oversight by tightening control over items like RUO reagents and specimen collection devices.

The firm is developing a kitted version of the four-biomarker combination test, and it plans to commercialize them in the EU and US markets.